List of Lotemax Sm drug patents

Lotemax Sm is owned by Bausch And Lomb Inc.

Lotemax Sm contains Loteprednol Etabonate.

Lotemax Sm has a total of 1 drug patent out of which 0 drug patents have expired.

Lotemax Sm was authorised for market use on 22 February, 2019.

Lotemax Sm is available in gel;ophthalmic dosage forms.

Lotemax Sm can be used as treatment of post-operative inflammation and pain following ocular surgery.

The generics of Lotemax Sm are possible to be released after 23 December, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596107 BAUSCH AND LOMB INC Ophthalmic suspension composition
Dec, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Strength (NS) Feb 22, 2022

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Market Authorisation Date: 22 February, 2019

Treatment: Treatment of post-operative inflammation and pain following ocular surgery

Dosage: GEL;OPHTHALMIC

How can I launch a generic of LOTEMAX SM before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in